News for argenx SE (ARGX.BR)

In a recent update, Bank of America analyst Tazeen Ahmad adjusted the price target for Argenx (ARGX), bringing it down to EUR 680 from the previous EUR 736. Des

Focus on developing antibody-based therapies for severe autoimmune diseases.Strong pipeline with multiple late-stage clinical trials.Risks include clinical tri

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires.

Summary argenx SE (ARGX), a prominent global immunology company, has announced that its Annual General Meeting of shareholders will take place on May 27, 2025,

Argenx (ARGX) to hold its Annual General Meeting on May 27, 2025, at Hilton Amsterdam Schiphol. Key agenda items include the adoption of the 2024 annual

Option Care Health (OPCH) experienced a share price decline following Argenx's (ARGX) announcement of FDA approval for Vyvgart Hytrulo as a self-administered pr

**media[592902]**

Quick Highlights for Investors: Argenx (ARGX) has received FDA approval for Vyvgart Hytrulo, enabling self-injection for autoimmune disorders. Wall Stree

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-i...

U.S. stock futures showed slight gains in early evening trading as investors looked for stability following a volatile period. The S&P 500 rose by 0.4%, the Nas

Argenx (ARGX) has received approval from the U.S. Food and Drug Administration for a new self-injection method of administering VYVGART Hytrulo. This developmen

**media[592091]**

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.

**media[559807]**

On March 7, 2025, argenx SE (ARGX), a global immunology company, announced the presentation of clinical trial and real-world data for its products VYVGART® and

Product Net Sales: $737 million for Q4 and $2.2 billion for the full year 2024.Total Operating Income: $761 million for Q4 and $2.3 billion for the full year 2

Feb 27, 2025 / 01:30PM GMTOperator Good morning. My name is Rob, and I will be your conference operator today. I would like to welcome everyone to the call. (Op

argenx SE (NASDAQ:ARGX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsBeth DelGiacco - Vice President, Corporate...

**media[551690]**